Rare Infection in Transplant Recipients Linked to Donors
|
By LabMedica International staff writers Posted on 01 Jun 2017 |

Image: Mycoplasma hominis, the bacteria responsible for a rare infection in transplant recipients (Photo courtesy of the Mayo Clinic).
The way in which heart and lung transplant recipients acquired a specific species of bacteria, Mycoplasma hominis, had been previously undefined, and the bacterium was difficult to test for and detect. Originally, this bacterium was considered to reside exclusively in, and be a potential pathogen of the area of the reproductive and urinary organs.
M. hominis resists most antibiotics, and the three antibiotic treatment recommendations for these infections are neither standard for post-transplant recipient care nor are they standard in therapy regimens for surgical site infections. Heart and lung transplant recipient infection caused by M. hominis may present with, surgical site infection and mediastinitis, which is an inflammation of tissue in mid-chest.
Scientists at the Mayo Clinic investigated lung and heart-lung transplants between 1998 and July 2015 at the Mayo Clinic. Seven previously unreported cases of transplant recipients with M. hominis infection were discovered. In each case, pre-transplant sputum cultures had tested negative for M. hominis. A literature review since 1950 found 15 cases of M. hominis infection in lung, heart or heart-lung transplant recipients. The way the bacteria spread remained uncertain. Given its normal residence in the genitourinary tract, some speculated that infection arose from urinary catheter placement during the transplant surgery.
Bronchoalveolar lavage samples were submitted for detecting organisms commonly found in immunocompromised hosts undergoing clinically indicated bronchoscopy were tested for M. hominis DNA. DNA was extracted on the MagNA Pure LC instrument using the MagNA Pure total nucleic acid isolation kit. Common testing methods have proven insufficient in identifying the bacteria, but the use of polymerase chain reaction offered a more time-sensitive and specific test for the bacteria. With this method, the scientists were able to focus in on a certain portion of DNA and then create multiple copies to amplify the segment. Polymerase chain reaction detection reduces the time to detect M. hominis to a few hours, compared to the two to five days needed for a culture media test.
Mark E. Wylam, MD, the lead investigator said, “These findings could affect how we approach the evaluation of organ donors. If potential transmission of these harmful bacteria can be identified and addressed, the recipient will face a decreased risk of infection and its serious complications. This study shows us that surveillance of both donor and recipient are important in recognizing M. hominis and the infection it can cause.” The study was published in the May 2017 issue of the journal EbioMedicine.
M. hominis resists most antibiotics, and the three antibiotic treatment recommendations for these infections are neither standard for post-transplant recipient care nor are they standard in therapy regimens for surgical site infections. Heart and lung transplant recipient infection caused by M. hominis may present with, surgical site infection and mediastinitis, which is an inflammation of tissue in mid-chest.
Scientists at the Mayo Clinic investigated lung and heart-lung transplants between 1998 and July 2015 at the Mayo Clinic. Seven previously unreported cases of transplant recipients with M. hominis infection were discovered. In each case, pre-transplant sputum cultures had tested negative for M. hominis. A literature review since 1950 found 15 cases of M. hominis infection in lung, heart or heart-lung transplant recipients. The way the bacteria spread remained uncertain. Given its normal residence in the genitourinary tract, some speculated that infection arose from urinary catheter placement during the transplant surgery.
Bronchoalveolar lavage samples were submitted for detecting organisms commonly found in immunocompromised hosts undergoing clinically indicated bronchoscopy were tested for M. hominis DNA. DNA was extracted on the MagNA Pure LC instrument using the MagNA Pure total nucleic acid isolation kit. Common testing methods have proven insufficient in identifying the bacteria, but the use of polymerase chain reaction offered a more time-sensitive and specific test for the bacteria. With this method, the scientists were able to focus in on a certain portion of DNA and then create multiple copies to amplify the segment. Polymerase chain reaction detection reduces the time to detect M. hominis to a few hours, compared to the two to five days needed for a culture media test.
Mark E. Wylam, MD, the lead investigator said, “These findings could affect how we approach the evaluation of organ donors. If potential transmission of these harmful bacteria can be identified and addressed, the recipient will face a decreased risk of infection and its serious complications. This study shows us that surveillance of both donor and recipient are important in recognizing M. hominis and the infection it can cause.” The study was published in the May 2017 issue of the journal EbioMedicine.
Latest Microbiology News
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
Bruker Corporation has acquired the DISQVER clinical metagenomics platform from Noscendo GmbH, expanding its next-generation sequencing infection detection portfolio. Following the acquisition, DISQVER... Read more








